Clinical Features of Cough-Variant Asthma
Cough-variant asthma (CVA) presents as chronic cough that is the predominant or sole symptom of asthma, occurring without the typical asthmatic symptoms of dyspnea, wheezing, or chest tightness 1.
Key Diagnostic Features
Primary Presentation
- Isolated chronic cough as the main or only symptom, distinguishing it from classic asthma where cough accompanies wheezing and dyspnea 1
- Cough may serve as a harbinger of future typical asthmatic episodes, or remain the sole manifestation indefinitely 1
- Accounts for 24-42% of chronic cough cases in adult nonsmokers 1, 2
Physical Examination and Baseline Testing
A critical pitfall: Physical examination and spirometry findings may be entirely normal 1. This normal presentation is what makes CVA diagnostically challenging and frequently leads to underdiagnosis. Unlike classic asthma, you cannot rely on wheezing on exam or obvious spirometric abnormalities to make the diagnosis.
Pulmonary Function Characteristics
- Baseline spirometry is typically normal or near-normal 1
- When abnormalities exist, they manifest as:
Bronchial Hyperresponsiveness
- Methacholine challenge testing demonstrates bronchial hyperresponsiveness, confirming the asthmatic nature of the condition 1
- However, CVA patients show lesser degrees of bronchial hyperresponsiveness compared to classic asthma 1, 5
- The distribution shows lower percentages of moderate-to-severe airway hyperresponsiveness (41.72% in CVA vs 64.70% in classic asthma) 5
Important caveat: A positive methacholine test is consistent with but NOT diagnostic of CVA—definitive diagnosis requires documented resolution of cough with anti-asthmatic therapy 1.
Pathophysiological Distinctions
Cough Reflex Sensitivity
CVA patients comprise a distinct subgroup with significantly more sensitive cough reflexes compared to both healthy individuals and patients with typical asthma 1. This heightened cough reflex sensitivity explains why these patients cough without the typical triggers that cause wheezing in classic asthma.
Inflammatory Profile
- Lower airway eosinophilia compared to classic asthma (lower sputum eosinophil percentages) 5
- Type 2 inflammation present in approximately 50-65% of CVA patients 6
- Two distinct molecular endotypes identified 7:
- Mixed-inflammatory CVA (higher eosinophils, neutrophils, and type 2/1/3 cytokines)
- Pauci-inflammatory CVA (minimal inflammation, worse treatment response)
- Subepithelial layer thickening (airway remodeling) is present even in CVA 1
Inflammatory Subtype Distribution
When classified by induced sputum cell counts 5:
- Lower proportion of eosinophilic and mixed granulocytic subtypes compared to classic asthma (56.0% vs 67.19%)
- Paucigranulocytic subtype has lowest proportion
- Mixed granulocytic subtype most common in both CVA and classic asthma
Demographic and Clinical Characteristics
Patient Demographics
- Younger age compared to classic asthma patients 5
- Higher prevalence in females 5
- Shorter disease duration at presentation 5
Associated Features
- Higher prevalence of allergic rhinitis as comorbidity 3
- More frequent family history of allergic diseases 3
- Cough often triggered by allergen exposure 3
- Elevated fractional exhaled nitric oxide (FeNO ≥25 ppb) in approximately half of patients, associated with allergic features 3
Diagnostic Confirmation
The diagnosis is only definitively established after documented resolution of cough with anti-asthmatic therapy 1. This therapeutic trial serves as both diagnostic test and treatment, distinguishing CVA from other causes of chronic cough like nonasthmatic eosinophilic bronchitis, which may also respond to corticosteroids but lacks airway hyperresponsiveness 1.
Timeline for Response
- Partial improvement often occurs after 1 week of inhaled bronchodilator therapy 1
- Complete cough resolution may require up to 8 weeks of inhaled corticosteroid treatment 1
- Greatest improvement in cough severity observed after 4 months of treatment 6
Prognostic Features
Treatment Response Predictors
- Type 2 inflammation predicts better treatment response (HR=1.733 for complete cough resolution) 6
- Approximately 36.5% of patients have persistent cough despite 6 months of treatment 6
- Pauci-inflammatory CVA shows significantly higher cough persistence compared to mixed-inflammatory CVA 7
Poor Response Indicators
Patients with persistent cough despite treatment tend to have 6:
- Older age
- Longer disease duration
- Higher baseline sputum neutrophil counts
- Lower sputum eosinophil counts
- Lower FeNO levels
- Lower proportion of type 2 inflammation (42.4% vs 65.3%)
Small Airway Disease Impact
When small airway dysfunction is present (FEF50% <70%), anti-asthmatic medication improves symptoms but cannot reverse the small airway obstruction over a 1-year period 4. This suggests structural changes that persist despite anti-inflammatory treatment.